Provided by Tiger Trade Technology Pte. Ltd.

iShares U.S. Healthcare ETF

69.92
-0.0800-0.11%
Post-market: 69.920.00000.00%19:30 EDT
Volume:255.90K
Turnover:17.93M
Market Cap:3.60B
PE:6.30
High:70.64
Open:70.46
Low:69.84
Close:70.00
52wk High:74.59
52wk Low:56.44
Shares:51.55M
Float Shares:51.55M
Volume Ratio:0.70
T/O Rate:0.50%
Dividend:0.81
Dividend Rate:1.16%
EPS(TTM):11.10
EPS(LYR):3.06
ROE:6.01%
ROA:0.87%
PB:1.29
PE(LYR):22.86

Loading ...

UnitedHealth (UNH) Gets a Buy from Bernstein

TIPRANKS
·
Sep 04

Wells Fargo Adjusts Price Target on Merck & Co. to $170 From $150, Keeps Overweight Rating

MT Newswires Live
·
Sep 04

AbbVie Closes $10.9B Takeover of Apogee, Its Largest Deal Since 2019, With Earnings Lift Expected From 2032

Stock News
·
Sep 04

Perrigo Co. PLC Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
Sep 04

Eli Lilly Stock (LLY) Gets a Bullish Note from JPMorgan Chase

TIPRANKS
·
Sep 04

Sector Update: Healthcare Stocks Higher Thursday Afternoon

MT Newswires Live
·
Sep 04

Medicare Advantage Patients Who Get Diagnosed with Alzheimer's or Other Serious Diseases are Ditching Their Plans - and it Can Cost Them

Dow Jones
·
Sep 04

Eisai’s Lenvima Combo Trial in Liver Cancer Ends With Mixed but Market-Relevant Results

TIPRANKS
·
Sep 04

Summit Therapeutics Says it is Beating Merck with Its Cancer Drug

Dow Jones
·
Sep 04

AbbVie's Phase 3 Study of Etentamig in Multiple Myeloma Meets Dual Primary Endpoints

MT Newswires Live
·
Sep 03

AbbVie Says Blood Cancer Drug Met Dual Primary Endpoints in Phase 3 Study

Dow Jones
·
Sep 03

AbbVie announces Phase 3 Cervino study met dual primary endpoints of ORR, PFS

TIPRANKS
·
Sep 03

AbbVie's Blood Cancer Drug Meets Late-Stage Trial Goals

Reuters
·
Sep 03

Abbvie - Phase 3 Cervino Study Met Dual Primary Endpoints; Full Results to be Presented Sept 23-26

THOMSON REUTERS
·
Sep 03

Abbvie - Etentamig Demonstrates Low Rates of Cytokine Release Syndrome and Fatal Infections

THOMSON REUTERS
·
Sep 03

Abbvie - Etentamig Achieves 74% Orr and 60% Risk Reduction in Phase 3 Cervino Trial

THOMSON REUTERS
·
Sep 03

Abbvie Announces Positive Topline Results from the Phase 3 Cervino Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma

THOMSON REUTERS
·
Sep 03

AbbVie Closes $10.9 Billion Acquisition of Apogee Therapeutics

MT Newswires Live
·
Sep 03

Apogee Therapeutics Shares Face NASDAQ Suspension as Company Moves to Delist After AbbVie Merger

Reuters
·
Sep 03

Aspen Sees Mounjaro Africa Sales Above $124 Million in 2027

Reuters
·
Sep 03